Plain-English Summary
STEP 4 is the clearest maintenance warning shot: after an initial semaglutide run-in, people who kept taking semaglutide kept losing weight, while those switched to placebo regained weight on average.
Key Findings
- Participants lost a mean 10.6% of body weight during the 20-week semaglutide run-in before randomization.
- From week 20 to week 68, continued semaglutide led to an additional mean body-weight change of -7.9%, while switching to placebo led to mean regain of +6.9%.
- The between-group difference for body-weight change from week 20 to week 68 was -14.8 percentage points.
- Waist circumference, systolic blood pressure, and physical-function scores improved more with continued semaglutide than with placebo.
- Gastrointestinal events were reported by 49.1% of participants continuing semaglutide versus 26.1% after switch to placebo; discontinuation due to adverse events was similar between groups.
Limitations
- Withdrawal design enriches for people who tolerated and responded enough to semaglutide during run-in, so it does not represent all starters.
- The study answers what happened after stopping or continuing at 20 weeks, not what should happen over many years of obesity care.
- Participants had structured trial follow-up and lifestyle intervention, which may differ from real-world prescribing and adherence.
Why It Matters
This page should anchor claims about GLP-1 discontinuation and weight regain. The point is not that everyone must stay on a drug forever, but that the trial directly shows obesity pharmacotherapy behaves like chronic-treatment support for many responders.
Viral Vitalism Verdict
Extremely useful for consumer framing because it separates initial weight loss from maintenance. Do not sell it as destiny, but do use it to challenge simplistic 'just take it for a few months' narratives.